PE20221727A1 - Dosificacion qw de compuestos peptidicos agonistas del receptor de gip y sus usos - Google Patents
Dosificacion qw de compuestos peptidicos agonistas del receptor de gip y sus usosInfo
- Publication number
- PE20221727A1 PE20221727A1 PE2022002091A PE2022002091A PE20221727A1 PE 20221727 A1 PE20221727 A1 PE 20221727A1 PE 2022002091 A PE2022002091 A PE 2022002091A PE 2022002091 A PE2022002091 A PE 2022002091A PE 20221727 A1 PE20221727 A1 PE 20221727A1
- Authority
- PE
- Peru
- Prior art keywords
- receptor agonist
- agonist peptide
- gip receptor
- peptide compounds
- dosage
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062994721P | 2020-03-25 | 2020-03-25 | |
| PCT/JP2021/014422 WO2021193983A2 (en) | 2020-03-25 | 2021-03-25 | Qw dosing of gip receptor agonist peptide compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221727A1 true PE20221727A1 (es) | 2022-11-04 |
Family
ID=75674909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002091A PE20221727A1 (es) | 2020-03-25 | 2021-03-25 | Dosificacion qw de compuestos peptidicos agonistas del receptor de gip y sus usos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230143604A1 (enExample) |
| EP (1) | EP4126920A2 (enExample) |
| JP (1) | JP2023524603A (enExample) |
| KR (1) | KR20220157409A (enExample) |
| CN (1) | CN115916812A (enExample) |
| AR (1) | AR121649A1 (enExample) |
| AU (1) | AU2021243671A1 (enExample) |
| BR (1) | BR112022019110A2 (enExample) |
| CA (1) | CA3172241A1 (enExample) |
| CL (1) | CL2022002597A1 (enExample) |
| CO (1) | CO2022014960A2 (enExample) |
| EC (1) | ECSP22074715A (enExample) |
| IL (1) | IL296219A (enExample) |
| MX (1) | MX2022011729A (enExample) |
| PE (1) | PE20221727A1 (enExample) |
| PH (1) | PH12022552561A1 (enExample) |
| TW (1) | TW202202517A (enExample) |
| WO (1) | WO2021193983A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024525843A (ja) * | 2021-07-16 | 2024-07-12 | ぺプ２タンゴ セラピューティクス インコーポレイテッド | マルチアゴニストペプチドを含む組成物並びに製造及び使用方法 |
| WO2023139106A2 (en) * | 2022-01-18 | 2023-07-27 | Novo Nordisk A/S | Long-acting gipr antagonists |
| WO2025154020A1 (en) * | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Improved gip receptor agonist peptide compounds and uses thereof |
| WO2025154021A1 (en) * | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Improved gip receptor agonist peptide compounds and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
| EP1302462A4 (en) | 2000-07-17 | 2007-07-18 | Takeda Pharmaceutical | SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF |
| BR0315815A (pt) | 2002-11-01 | 2005-09-13 | Takeda Pharmaceutical | Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto |
| AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
| US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| EP1669352A4 (en) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | THIAZOLINE DERIVATIVE AND ITS USE |
| WO2005058823A1 (ja) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | ウレア誘導体、その製造法及び用途 |
| US7456218B2 (en) | 2003-12-25 | 2008-11-25 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
| WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
| WO2005087710A1 (ja) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | アミノフェニルプロパン酸誘導体 |
| JP4859665B2 (ja) | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| US8263545B2 (en) * | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
| US8957070B2 (en) | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
| WO2006121904A1 (en) * | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use |
| EP1916234B1 (en) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| US20090054435A1 (en) | 2005-07-29 | 2009-02-26 | Hiroshi Imoto | Phenoxyalkanoic Acid Compound |
| JP4094660B1 (ja) | 2005-08-10 | 2008-06-04 | 武田薬品工業株式会社 | 糖尿病治療剤 |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| AU2007265966B2 (en) | 2006-06-27 | 2012-05-17 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
| JP5399244B2 (ja) * | 2006-08-17 | 2014-01-29 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | 選択可能な特性を持つｄｐｐ−ｉｖ耐性ｇｉｐハイブリッドポリペプチド |
| EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| CN101573357B (zh) | 2006-10-19 | 2013-01-23 | 武田药品工业株式会社 | 吲哚化合物 |
| WO2008093639A1 (ja) | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| AU2008215490A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of PPAR-gamma |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| EP2157859A4 (en) | 2007-06-19 | 2011-01-12 | Takeda Pharmaceutical | INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE |
| KR20130133103A (ko) * | 2008-08-07 | 2013-12-05 | 입센 파마 에스.에이.에스 | Ｎ-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(ｇｉｐ)의 유사체 |
| WO2010016936A1 (en) * | 2008-08-07 | 2010-02-11 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide |
| JOP20190211A1 (ar) * | 2017-03-31 | 2019-09-15 | Takeda Pharmaceuticals Co | ببتيد منشط لمستقبل gip |
| IL296592A (en) * | 2020-03-25 | 2022-11-01 | Takeda Pharmaceuticals Co | Qd dosing of gip receptor agonist peptide compounds and uses thereof |
-
2021
- 2021-03-25 IL IL296219A patent/IL296219A/en unknown
- 2021-03-25 PE PE2022002091A patent/PE20221727A1/es unknown
- 2021-03-25 EP EP21721645.6A patent/EP4126920A2/en active Pending
- 2021-03-25 PH PH1/2022/552561A patent/PH12022552561A1/en unknown
- 2021-03-25 WO PCT/JP2021/014422 patent/WO2021193983A2/en not_active Ceased
- 2021-03-25 AU AU2021243671A patent/AU2021243671A1/en active Pending
- 2021-03-25 CA CA3172241A patent/CA3172241A1/en active Pending
- 2021-03-25 BR BR112022019110A patent/BR112022019110A2/pt unknown
- 2021-03-25 AR ARP210100729A patent/AR121649A1/es unknown
- 2021-03-25 MX MX2022011729A patent/MX2022011729A/es unknown
- 2021-03-25 KR KR1020227034445A patent/KR20220157409A/ko not_active Ceased
- 2021-03-25 JP JP2023502028A patent/JP2023524603A/ja active Pending
- 2021-03-25 TW TW110110875A patent/TW202202517A/zh unknown
- 2021-03-25 CN CN202180023693.4A patent/CN115916812A/zh active Pending
- 2021-03-25 US US17/914,013 patent/US20230143604A1/en active Pending
-
2022
- 2022-09-23 EC ECSENADI202274715A patent/ECSP22074715A/es unknown
- 2022-09-23 CL CL2022002597A patent/CL2022002597A1/es unknown
- 2022-10-20 CO CONC2022/0014960A patent/CO2022014960A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4126920A2 (en) | 2023-02-08 |
| WO2021193983A2 (en) | 2021-09-30 |
| BR112022019110A2 (pt) | 2023-01-17 |
| JP2023524603A (ja) | 2023-06-12 |
| TW202202517A (zh) | 2022-01-16 |
| ECSP22074715A (es) | 2022-10-31 |
| KR20220157409A (ko) | 2022-11-29 |
| US20230143604A1 (en) | 2023-05-11 |
| IL296219A (en) | 2022-11-01 |
| MX2022011729A (es) | 2022-10-13 |
| CN115916812A (zh) | 2023-04-04 |
| CA3172241A1 (en) | 2021-09-30 |
| PH12022552561A1 (en) | 2024-04-22 |
| CL2022002597A1 (es) | 2023-06-02 |
| WO2021193983A8 (en) | 2023-05-25 |
| AU2021243671A1 (en) | 2022-10-13 |
| AR121649A1 (es) | 2022-06-22 |
| WO2021193983A3 (en) | 2021-11-04 |
| CO2022014960A2 (es) | 2022-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022002597A1 (es) | Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos | |
| CO2022014959A2 (es) | Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos | |
| CO2019012271A2 (es) | Péptido activador de receptor de gip | |
| UY40873A (es) | Compuestos cíclicos puenteados y composiciones farmacéuticas y usos de los mismos para modular la respuesta integrada al estrés y para tratar enfermedades relacionadas | |
| MX2019004616A (es) | Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina. | |
| CL2017001024A1 (es) | Formulación de buprenorfina inyectable | |
| MX2020011405A (es) | Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos. | |
| AR070026A1 (es) | Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus | |
| AR114325A1 (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
| CO2022009510A2 (es) | Compuestos activos frente a receptores nucleares | |
| AR114324A1 (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| ECSP18084449A (es) | Dispositivo de inyección mecánico para descargar múltiples formulaciones líquidas, incluso vacunas | |
| ECSP19019613A (es) | Compuestos de azaindazol para usar en lesiones de tendones y/o ligamentos | |
| MX2021015543A (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo. | |
| AR101806A1 (es) | Derivados de 1-acetil-4-amino-1,2,3,4-tetrahidroquinolina, composición farmacéutica que los comprende y su uso en el tratamiento de afecciones mediadas por un inhibidor de bromodominio | |
| MX390507B (es) | Compuestos de amida y su uso. | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
| DOP2019000071A (es) | Compuestos de indazol para usar en lesiones de tendones y/o ligamentos | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| CO2020002967A2 (es) | Desinfectante novedoso para criaderos | |
| AR102248A1 (es) | Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes | |
| AR121581A1 (es) | Formulaciones líquidas de análogos de glucagón | |
| UY37166A (es) | Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano | |
| MX2021011007A (es) | Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco. |